---
import BaseLayout from '../layouts/BaseLayout.astro';

const title = "Project Information - ASPS Therapeutics Discovery Initiative";
const description = "Comprehensive documentation of the ASPS Therapeutics Discovery Initiative: Molecular pathology, research methodology, roadmap, and datasets for Alveolar Soft Part Sarcoma.";
---

<BaseLayout title={title} description={description}>
  <main class="container-main py-12 bg-white text-gray-900">
    <article itemscope itemtype="https://schema.org/ResearchProject">
      <header class="mb-12 border-b pb-8">
        <h1 class="page-title text-purple-900" itemprop="name">ASPS Therapeutics Discovery Initiative</h1>
        <p class="text-lead" itemprop="description">
          A computational and experimental research program dedicated to finding new therapeutic targets for Alveolar Soft Part Sarcoma (ASPS) through integrated AI agents and wet-lab validation.
        </p>
      </header>

      <section class="mb-12">
        <h2 class="section-heading">1. Project Overview</h2>
        <p class="mb-4 text-lg leading-relaxed">
          The ASPS Therapeutics Discovery Initiative (Sarkome) operates as a "Single Asset Entity" focused on identifying, validating, and licensing therapeutic assets for ASPS. We replace traditional R&D infrastructure with an agentic AI core that filters global biomedical data to generate high-confidence Target Product Profiles (TPPs).
        </p>
      </section>

      <section class="mb-12">
        <h2 class="section-heading">2. Molecular Pathology</h2>
        <div class="info-box">
          <ul class="space-y-4">
            <li class="flex flex-col md:flex-row md:items-start gap-2">
              <strong class="min-w-[150px] text-purple-700">Disease:</strong>
              <span>Alveolar Soft Part Sarcoma (ASPS), a rare, translocation-associated sarcoma.</span>
            </li>
            <li class="flex flex-col md:flex-row md:items-start gap-2">
              <strong class="min-w-[150px] text-purple-700">Driver Mutation:</strong>
              <span><strong>t(X;17)(p11;q25)</strong> translocation resulting in the <strong>ASPSCR1-TFE3</strong> fusion oncoprotein.</span>
            </li>
            <li class="flex flex-col md:flex-row md:items-start gap-2">
              <strong class="min-w-[150px] text-purple-700">Mechanism:</strong>
              <span>The fusion protein acts as a constitutively active transcription factor, upregulating MET signaling, angiogenesis (VEGF), and immune evasion pathways.</span>
            </li>
            <li class="flex flex-col md:flex-row md:items-start gap-2">
              <strong class="min-w-[150px] text-purple-700">Vulnerabilities:</strong>
              <span>Extreme angiogenesis dependence and transcriptional addiction to the TFE3 fusion program.</span>
            </li>
          </ul>
        </div>
      </section>

      <section class="mb-12">
        <h2 class="section-heading">3. Research Methodology: The Agentic Core</h2>
        <p class="mb-6 text-lg">
          Our discovery pipeline utilizes three specialized AI agents to process data and generate candidates:
        </p>
        
        <div class="grid gap-6 md:grid-cols-3">
          <div class="border p-4 rounded shadow-sm">
            <h3 class="font-bold text-lg mb-2 text-purple-700">Agent A: The Miner</h3>
            <p class="text-sm text-gray-600 mb-2">Knowledge Extraction</p>
            <p class="text-sm">Scrapes PubMed/ChEMBL to find hidden relationships between TFE3 and potential inhibitors using Large Language Models.</p>
          </div>
          <div class="border p-4 rounded shadow-sm">
            <h3 class="font-bold text-lg mb-2 text-purple-700">Agent B: The Physicist</h3>
            <p class="text-sm text-gray-600 mb-2">Structural Validation</p>
            <p class="text-sm">Uses AlphaFold 3 and DiffDock to simulate binding affinity (Gibbs Free Energy) of candidates against the ASPSCR1-TFE3 IDR.</p>
          </div>
          <div class="border p-4 rounded shadow-sm">
            <h3 class="font-bold text-lg mb-2 text-purple-700">Agent C: The Skeptic</h3>
            <p class="text-sm text-gray-600 mb-2">Safety & Toxicity</p>
            <p class="text-sm">Filters for oral bioavailability (<500 Da), PAINS, and known toxicity using Tox21 and FDA databases.</p>
          </div>
        </div>
      </section>

      <section class="mb-12">
        <h2 class="section-heading">4. Roadmap</h2>
        <div class="space-y-6">
          <div>
            <h3 class="text-xl font-bold text-gray-800">Phase 1: Signal Identification (2026 Q1)</h3>
            <p class="text-gray-700">Data lake construction, agent deployment, and generation of the initial Target Product Profile (TPP).</p>
          </div>
          <div>
            <h3 class="text-xl font-bold text-gray-800">Phase 2: Biological Proof (2026 Q2â€“Q4)</h3>
            <p class="text-gray-700">Wet-lab validation of top 3 compounds via CROs (WuXi AppTec, Charles River). Assays: IC50 on ASPS-1 cell lines, Western Blot for TFE3 levels.</p>
          </div>
          <div>
            <h3 class="text-xl font-bold text-gray-800">Phase 3: Regulatory Asset Generation (2027)</h3>
            <p class="text-gray-700">ADME/Tox panels and Pre-IND meeting request with the FDA for a Basket Trial design (ASPS + RCC).</p>
          </div>
        </div>
      </section>

      <section class="mb-12">
        <h2 class="section-heading">5. Datasets & Endpoints</h2>
        <p class="mb-4">We provide machine-readable access to our findings:</p>
        <ul class="list-disc pl-6 space-y-2 text-purple-700 font-mono">
          <li><a href="/machine/knowledge.json" class="hover:underline">/machine/knowledge.json</a> - Knowledge graph of entities.</li>
          <li>/machine/asps-targets.json - Predicted therapeutic targets.</li>
          <li>/machine/datasets.json - Index of aggregated transcriptomic data.</li>
        </ul>
      </section>

      <footer class="mt-16 pt-8 border-t text-gray-600 text-sm">
        <p>Last updated: December 2025</p>
        <p>Contact: <a href="mailto:research@sarkome.com" class="text-purple-600 hover:underline">research@sarkome.com</a></p>
      </footer>
    </article>
  </main>

  <!-- Comprehensive JSON-LD for LLMs -->
  <script type="application/ld+json">
    {
      "@context": "https://schema.org",
      "@graph": [
        {
          "@type": "ResearchProject",
          "@id": "https://sarkome.com/#project",
          "name": "ASPS Therapeutics Discovery Initiative",
          "alternateName": "Sarkome",
          "description": "A computational and experimental research program dedicated to finding new therapeutic targets for Alveolar Soft Part Sarcoma.",
          "parentOrganization": {
            "@type": "Organization",
            "name": "Sarkome",
            "url": "https://sarkome.com"
          },
          "areaServed": "Global",
          "knowsAbout": [
            {
              "@type": "MedicalCondition",
              "name": "Alveolar Soft Part Sarcoma",
              "alternateName": "ASPS",
              "associatedAnatomy": {
                "@type": "AnatomicalStructure",
                "name": "Soft tissue"
              },
              "possibleTreatment": ["Atezolizumab", "Pazopanib", "Anti-angiogenic agents"]
            },
            "Computational Biology",
            "Drug Discovery",
            "ASPSCR1-TFE3 fusion"
          ]
        },
        {
          "@type": "WebPage",
          "@id": "https://sarkome.com/project-info",
          "url": "https://sarkome.com/project-info",
          "name": "Project Information - Sarkome",
          "description": "Detailed documentation of the ASPS Therapeutics Discovery Initiative for researchers and AI agents.",
          "isPartOf": {
            "@id": "https://sarkome.com/#website"
          },
          "about": {
            "@id": "https://sarkome.com/#project"
          }
        }
      ]
    }
  </script>
</BaseLayout>
